Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size
2 studies found for:    22261379 [PUBMED-IDS]

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
Conditions: Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma
Interventions: Drug: G-CSF (filgrastim);   Drug: Cytosine arabinoside with G-CSF (filgrastim)
2 Unknown † Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.
Condition: Multiple Myeloma
Interventions: Drug: G-CSF (filgrastim);   Drug: Cytosine arabinoside + G-CSF (filgrastim)
To Top

† Indicates status has not been verified in more than two years